Author: news_poster
Posted: Tue Aug 23, 2011 2:00 am
Our concerns about the approval of injectable naltrexone (Vivitrol) for treatment of opioid dependence turned on three points. First, that the US Food and Drug Administration (FDA) accepted a single trial of injectable naltrexone in Russia, unpublished at the time, as primary evidence of efficacy. Second, that the study did not adequately assess risk of post-treatment overdose in trial participants. Third, that it was ethically questionable to do a placebo-based trial given the proven efficacy of methadone and buprenorphine and the known risk of mortality in patients offered counselling alone. (Source: LANCET)
Source: MedWorm Query: Buprenorphine
MedWorm.com provides a medical RSS filtering service. Data from over 6000 medical RSS feeds is collected and output via different categories. This feed contains the latest headlines from the user generated query: Buprenorphine
